A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease
Work
Year: 2022
Type: article
Abstract: Nonalcoholic fatty liver disease (NAFLD) is a metabolic disease mainly on account of hypercholesterolemia and may progress to cirrhosis and hepatocellular carcinoma. The discovery of effective therapy... more
Source: Journal of Nanobiotechnology
Institution Fudan University
Cites: 53
Cited by: 15
Related to: 10
FWCI: 3.604
Citation percentile (by year/subfield): 100
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: gold
APC paid (est): $2,686